Hetelekidis S, Collins L, Silver B, Manola J, Gelman R, Cooper A, Lester S, Lyons J A, Harris J R, Schnitt S J
Joint Center for Radiation Therapy, Boston, Massachusetts, USA.
Cancer. 1999 Jan 15;85(2):427-31.
The treatment of ductal carcinoma in situ (DCIS) remains controversial, particularly in regard to the selection of patients who may be appropriately treated with wide excision alone. To help identify such patients, the authors assessed prognostic factors for local recurrence in patients with DCIS treated with excision alone.
The study population consisted of 59 patients diagnosed with DCIS between 1985 and 1990. All had been treated with excision alone, had their histologic slides available for re-review by a study pathologist, and had negative margins of excision on review. The median age at diagnosis was 54 years, and the median follow-up time was 95.5 months. Ninety-six percent presented with mammographic findings only; all patients had a reexcision. The size of the DCIS was assessed by the total number of low-power fields (LPF) in which DCIS was present (median LPF = 5).
Ten patients experienced a local recurrence (LR) at 5-132 months (median, 37 months) after excision. The actuarial 5-year LR rate was 10%. Four of the recurrences were invasive carcinomas, and 6 were DCIS. No patients have developed metastatic disease or have died of disease. Lesion size >5 LPF was the only significant prognostic factor for local recurrence on univariate analysis (3% vs. 17% for < or = 5 vs. > or = 5 LPF, P = 0.02) and in proportional hazards models. Although patients with nuclear Grade 3 lesions had a higher LR rate than those with nuclear Grade 1 and 2 lesions (18% vs. 6% and 5%, respectively) and patients with close margins (< or = 1 mm) had a higher LR rate than patients with negative margins (>1 mm) (25% vs. 8%), these differences did not reach statistical significance. Among the 19 cases with margins negative by more than 1 mm, lesion size < or = 5 LPF, and nuclear Grade 1 or 2, there were no LRs; by contrast, the remaining 40 patients had a 5-year actuarial LR rate of 15% (P = 0.08).
Lesion size was the only statistically significant prognostic factor for local recurrence in this series of patients with DCIS treated with excision alone. Other factors, such as margin status and nuclear grade, may also be useful in the identification of patients with DCIS who can be managed with excision alone. However, the most reliable and reproducible method of assessing these factors and the best way to combine them have not been determined.
导管原位癌(DCIS)的治疗仍存在争议,尤其是在选择可能仅通过广泛切除就能得到恰当治疗的患者方面。为了帮助识别这类患者,作者评估了仅接受切除治疗的DCIS患者局部复发的预后因素。
研究人群包括1985年至1990年间诊断为DCIS的59例患者。所有患者均仅接受了切除治疗,其组织学切片可供研究病理学家重新审查,且复查时切除切缘阴性。诊断时的中位年龄为54岁,中位随访时间为95.5个月。96%的患者仅表现为乳腺X线检查结果;所有患者均接受了再次切除。DCIS的大小通过存在DCIS的低倍视野(LPF)总数来评估(中位LPF = 5)。
10例患者在切除后5 - 132个月(中位时间为37个月)出现局部复发(LR)。5年累计LR率为10%。其中4例复发为浸润性癌,6例为DCIS。没有患者发生转移性疾病或死于该疾病。在单因素分析中,病变大小>5 LPF是局部复发的唯一显著预后因素(≤5 LPF与>5 LPF的复发率分别为3%和17%,P = 0.02),在比例风险模型中也是如此。尽管核分级为3级的患者LR率高于核分级为1级和2级的患者(分别为18%、6%和5%),且切缘接近(≤1 mm)的患者LR率高于切缘阴性(>1 mm)的患者(25%与8%),但这些差异未达到统计学显著性。在切缘阴性超过1 mm、病变大小≤5 LPF且核分级为1级或2级的19例患者中,无LR发生;相比之下其余40例患者的5年累计LR率为15%(P = 0.08)。
在这组仅接受切除治疗的DCIS患者中,病变大小是局部复发唯一具有统计学意义的预后因素。其他因素,如切缘状态和核分级,在识别可仅通过切除治疗的DCIS患者中可能也有用。然而,评估这些因素最可靠且可重复的方法以及将它们结合的最佳方式尚未确定。